GXV 813
Alternative Names: GXV-813Latest Information Update: 11 Mar 2025
At a glance
- Originator Novartis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 11 Mar 2025 No development reported - Phase-I for Unspecified (In volunteers) in United Kingdom (unspecified route)